Ken Griffin Biodesix Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biodesix Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 2,600 shares of BDSX stock, worth $3,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,600

Previous 500 420.0%

Holding current value

$3,250

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.53 - $1.96 $12,752 - $16,336	8,335 Added 146.9%	14,009 $24,000
Q2 2024 Aug 14, 2024	BUY	$1.21 - $1.71 $6,865 - $9,702	5,674 New	5,674 $8,000
Q4 2023 Feb 14, 2024	SELL	$1.2 - $2.13 $22,135 - $39,289	-18,446 Reduced 41.34%	26,177 $48,000
Q3 2023 Nov 14, 2023	BUY	$1.04 - $1.74 $46,407 - $77,644	44,623 New	44,623 $73,000
Q4 2022 Feb 14, 2023	SELL	$0.98 - $2.3 $24,733 - $58,047	-25,238 Reduced 79.84%	6,373 $14,000
Q3 2022 Nov 14, 2022	BUY	$1.24 - $2.89 $4,977 - $11,600	4,014 Added 14.55%	31,611 $40,000
Q2 2022 Aug 15, 2022	BUY	$1.32 - $2.12 $13,157 - $21,132	9,968 Added 56.54%	27,597 $45,000
Q1 2022 May 16, 2022	SELL	$1.69 - $5.81 $53,547 - $184,089	-31,685 Reduced 64.25%	17,629 $30,000
Q4 2021 Feb 14, 2022	SELL	$4.09 - $8.67 $1,566 - $3,320	-383 Reduced 0.77%	49,314 $260,000
Q3 2021 Nov 15, 2021	SELL	$6.6 - $12.78 $29,178 - $56,500	-4,421 Reduced 8.17%	49,697 $409,000
Q2 2021 Aug 16, 2021	BUY	$12.14 - $20.35 $110,097 - $184,554	9,069 Added 20.13%	54,118 $714,000
Q1 2021 May 17, 2021	BUY	$16.87 - $31.21 $443,562 - $820,604	26,293 Added 140.18%	45,049 $915,000
Q4 2020 Feb 16, 2021	BUY	$10.89 - $20.16 $204,252 - $378,120	18,756 New	18,756 $378,000

Others Institutions Holding BDSX

# of Institutions

Shares Held

56.2M

Call Options Held

2.6K

Put Options Held

10.1K

View Full List

About BIODESIX INC

Ticker BDSX
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 39,982,000
Market Cap $50M
Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...

More about BDSX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account